Abstract
ObjectivesPrime focus of this study was to evaluate the availability and affordability of originator brands (OBs) and lowest price generics (LPGs) of prescribed biologic and non-biologic anticancer medicines.Design, settings and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have